Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Aiforia launches new AI platform

Aiforia Technologies

Translation: Original published in Finnish on 12/18/2025 at 8:20 am EET.

Aiforia announced on Wednesday the launch of a new generation AI platform that utilizes Vision Transformer technology. The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio. The news has no direct impact on our forecasts, but we view the increased efficiency in product development positively, as it partly mitigates risks related to the company's innovation capabilities after cost cuts and supports its long-term competitiveness.

The new Foundation Engine solution enhances model development

Aiforia announced on Wednesday that it is expanding its AI platform with a new solution called Foundation Engine, which is based on the Vision Transformer architecture. According to the company, the new solution combines so-called foundation models, pre-trained on extensive image datasets, with task-specific annotations made by pathologists. Aiforia highlights that the key benefits of the technology are the acceleration of AI model development and the improved generalizability of models to different image datasets. The new technology will be deployed in Aiforia's own product development and will also be integrated into the Aiforia Create development tool available to customers.

The company referred to the benefits of the expansion in its own product development earlier in the fall, so the launch does not come as a particular surprise or put pressure on forecast changes. In any case, the acceleration of model development supports the company's goals to improve its operational efficiency. Aiforia has recently focused on optimizing its cost structure and securing its path to profitability. In our view, more efficient product development through new technology mitigates the risks of cost savings to the company's innovation pace and supports the company's ability to maintain competitiveness in the long term. In addition to supporting the expansion of the product portfolio in the clinical segment, which is central to Aiforia's growth strategy, the technology also fundamentally strengthens Aiforia's product for its research customers who develop their own models on the Aiforia platform.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Læs mere på virksomhedsside

Key Estimate Figures19.11.2025

202425e26e
Omsætning2,93,35,1
vækst-%18,9 %16,4 %55,0 %
EBIT (adj.)-12,2-10,9-8,6
EBIT-% (adj.)-427,8 %-328,4 %-167,6 %
EPS (adj.)-0,41-0,39-0,28
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forumopdateringer

Her er Anttis kommentarer, efter at Aiforia har lanceret en ny CE-IVD-mærket AI-løsning til diagnosticering af mavekræft. Aiforia meddelte mandag...
for 18 timer siden
af Sijoittaja-alokas
15
Aiforias nye aktionærliste. Børsens guldhoved Timo Syrjälä er rykket op på en 41. plads. Aiforia Aiforia - Osakkeenomistajat Aiforia on lääketieteen...
i går
af TO
16
Ja, man kan ikke direkte udlede Aiforias omsætning fra de forskellige løsninger baseret på kræftprocenterne. Det er faktisk mere sandsynligt...
i går
af Vino Pino
10
De nye CE-IVD-mærkninger vil ikke nødvendigvis kunne ses i omsætningen i et stykke tid, men det øger markant potentialet for at blive et opk...
i går
af Jekkku
7
Ubestrideligt ja, ved gastroskopi udtages der prøver fra flere steder i mavesækken samt tolvfingertarmen, hvilket betyder, at antallet af rutinem...
i går
7
Jeg mener, at potentialet er meget større; jeg antager, at man med dette ville undersøge en betydelig del af PAD-prøverne fra maveslimhinden...
i går
af Poimija
8
I USA er det 1,5 % af alle kræftformer Stomach (Gastric) Cancer Key Statistics | American Cancer Society I EU-27 er det 2,8 % af alle. https...
i går
af Vino Pino
16
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.